QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Neptune Technologies & Bioresources, Inc. (NEPT) Granted ‘New Food Raw Material' Certification To Sell Krill Oil Nutraceutical Products In China 0 comments
    Jan 9, 2014 5:56 PM | about stocks: NEPT

    Biotechnology company Neptune Technologies & Bioresources, Inc. announced it has received "New Food Raw Material" certification in China. This enables the company to sell its krill oil nutraceutical products in China, including NKO, its premium krill oil, and EKO, its eco krill oil. China's National Health and Family Planning Commission found no quality or safety concerns, which affirms the strength of Neptune's products.

    China, with its population of more than 1.35 billion people, offers significant growth potential for Neptune. The consumer demand for nutraceutical products that support health and wellness continues to increase in China, and the company plans to capitalize on this important market. Neptune already has sales representation in China and is actively pursuing sales opportunities.

    Chiefly engaged in developing and commercializing marine-derived omega-3 polyunsaturated fatty acids (PUFAs), Neptune has patented a process for extracting oils from Antarctic krill. The company principally sells omega-3 PUFAs as bulk oil to its distributors, who then commercialize them under private labels mainly in the U.S., European and Australian nutraceutical markets. Serving as a dietary supplement to consumers, Neptune's products generally come in bulk oil or capsule form.

    Through its 49.95 percent voting rights in Acasti and its 96 percent voting rights in NeuroBioPharm, Inc., Neptune is additionally pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBio are respectively focused on researching and developing safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions as well as neurodegenerative and inflammation-related conditions. Acasti's lead prescription drug candidate is CaPre, which is a purified high omega-3 phospholipid concentrate derived from Neptune krill oil. CaPre is being developed to address the prevention and treatment of cardiometabolic disorders.

    For more information, visit Neptune's website at neptunebiotech.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: NEPT
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.